(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Figure out How to Store Your Gold Ventures: A Thorough Aide safely- Inside the cockpit of RAF tanker during defensive mission against Iranian drones
- Step by step instructions to Pick A Pre-owned vehicle Stage
- Gen Z workplace stereotypes were TV’s favorite punchline in 2025
- Have gravitational waves provided the first hint of primordial black holes born during the Big Bang?
- Grasping the Basics of Business Land Regulation
- SUVs Known for Their Looks As opposed to Their Capacity
- Paraplegic engineer becomes the first wheelchair user to blast into space
- JFK's granddaughter reveals terminal cancer diagnosis, criticizes cousin RFK Jr.
